GlobeNewswire: Cognition Therapeutics, Inc. Contains the last 10 of 135 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T16:32:31ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/26/2852233/0/en/Cognition-Therapeutics-Reports-Year-End-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=32472Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update2024-03-26T11:00:56Z<![CDATA[- Topline Results from SHINE Study in Mild-to-Moderate Alzheimer’s Expected mid-2024 -- On Track to Report Topline Results from SHIMMER Study in Mild-to-Moderate DLB in 2H 2024 - - 1Q 2024 Capital Raise Extends Cash Runway Through May 2025 -- Webcast Conference Call Scheduled Today at 8:00 a.m. ET -]]>https://www.globenewswire.com/news-release/2024/03/15/2846980/0/en/Cognition-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2023-Results.html?f=22&fvtc=4&fvtv=32472Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results2024-03-15T11:30:59Z<![CDATA[Conference Call and Live Audio Webcast Scheduled for March 26, 2024 Conference Call and Live Audio Webcast Scheduled for March 26, 2024]]>https://www.globenewswire.com/news-release/2024/03/14/2846694/0/en/Cognition-Therapeutics-Announces-Closing-of-11-5-Million-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=32472Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock2024-03-14T20:05:15Z<![CDATA[PURCHASE, N.Y., March 14, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced today the closing of its previously announced underwritten public offering of 6,571,428 shares of its common stock. Each share of common stock was sold at a price to the public of $1.75 per share. The gross proceeds to the Company from the offering were approximately $11.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from this offering to fund research, clinical development, process development and manufacturing of Cognition’s product candidates, working capital, capital expenditures and other general corporate purposes.]]>https://www.globenewswire.com/news-release/2024/03/12/2844241/0/en/Cognition-Therapeutics-Announces-Pricing-of-11-5-Million-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=32472Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock2024-03-12T00:16:05Z<![CDATA[PURCHASE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, today announced that it has priced an underwritten public offering of 6,571,428 shares of its common stock at an offering price of $1.75 per share of common stock. Cognition has also granted the underwriters a 30-day option to purchase up to 985,714 additional shares of its common stock sold in the offering on the same terms and conditions. The Company expects to close the offering on March 14, 2024, subject to the satisfaction of customary closing conditions.]]>https://www.globenewswire.com/news-release/2024/03/11/2844153/0/en/Cognition-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=32472Cognition Therapeutics Announces Proposed Public Offering of Common Stock2024-03-11T20:05:16Z<![CDATA[PURCHASE, N. Y., March 11, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, today announced that it has commenced an underwritten public offering (the “offering”) of shares of its common stock. Cognition also intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the aggregate number of shares of its common stock to be sold in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares of common stock to be sold in the proposed offering will be sold by Cognition.]]>https://www.globenewswire.com/news-release/2024/03/06/2841289/0/en/Cognition-Therapeutics-Presents-Analyses-at-AD-PD-2024-Correlating-Proteomic-Findings-with-Treatment-Effect-of-CT1812-in-Alzheimer-s-Disease-Studies.html?f=22&fvtc=4&fvtv=32472Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies2024-03-06T12:30:00Z<![CDATA[PITTSBURGH, March 06, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), is presenting results of proteomic and correlation analyses of two completed clinical studies at the AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference (March 5-9, 2024 in Lisbon, Portugal). The three posters, which are listed below, summarize proteomic analyses from the completed SEQUEL and SPARC studies, which were conducted in adults with mild-to-moderate Alzheimer’s disease.]]>https://www.globenewswire.com/news-release/2024/02/26/2835044/0/en/Cognition-Therapeutics-to-Present-at-the-TD-Cowen-Health-Care-Conference.html?f=22&fvtc=4&fvtv=32472Cognition Therapeutics to Present at the TD Cowen Health Care Conference2024-02-26T12:30:59Z<![CDATA[PURCHASE, N.Y., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced today that the Company’s president and CEO, Lisa Ricciardi will present at the TD Cowen 44th Annual Health Care Conference taking place March 4-6, 2024. During her presentation, Ms. Ricciardi will highlight Cognition’s pipeline progress, including upcoming clinical milestones and recent corporate achievements.]]>https://www.globenewswire.com/news-release/2024/02/06/2824357/0/en/New-Publication-Identifies-Key-Proteins-Involved-in-Amyloid-Oligomer-Binding-and-Supports-Mechanism-of-CT1812.html?f=22&fvtc=4&fvtv=32472New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT18122024-02-06T13:47:22Z<![CDATA[NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that collaborators at the University of Edinburgh, Scotland published findings in the journal, Acta Neuropathologica, (doi: 10.1007/s00401-023-02679-6) that provide new insight into the biology of Alzheimer’s disease that is consistent with our understanding of the role the σ-2 receptor has in regulating Aβ oligomer binding.]]>https://www.globenewswire.com/news-release/2024/01/04/2803877/0/en/Cognition-Therapeutics-CEO-Issues-Letter-to-Shareholders.html?f=22&fvtc=4&fvtv=32472Cognition Therapeutics CEO Issues Letter to Shareholders2024-01-04T12:30:00Z<![CDATA[Topline data from Phase 2 SHINE trial in patients with mild-to-moderate Alzheimer's disease anticipated in mid 2024]]>https://www.globenewswire.com/news-release/2023/11/16/2781746/0/en/Cognition-Therapeutics-Releases-New-Episode-of-Conversations-Podcast-Recorded-at-CTAD-with-Quantitative-EEG-Experts-Drs-Willem-de-Haan-and-Philip-Scheltens.html?f=22&fvtc=4&fvtv=32472Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens2023-11-16T12:30:35Z<![CDATA[PURCHASE, N.Y., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its seventh Conversations video podcast episode: “Quantitative EEG - Effects of CT1812 on Measures of Synaptic Function in Alzheimer’s Disease.” This episode will feature a review and interactive discussion of the results from Cognition’s Phase 2 SEQUEL study, which were presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference.]]>